Page 38 - 77_01

NANOTECNOLOGÍA
FARMACÉUTICA…..

28. Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R. & Rossi, J. J. (2009) Selection,
characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer
substrate siRNAs into HIV infected cells. Nucleic Acids Res. 37(9): 3094-3109.

29. Ross, C. A. & Shoulson, I. (2009) Huntington disease: Pathogeneis, biomarkers and approaches
to experimental therapeutics. Parkinsonism Relat. Disord. 15 Suppl 3: S135-138.

30. Tanahashi, H. & Yoshioka, K. (2008) RNA interference silencing of DRAL affects processing
of amyloid precursor protein. Neurosci. Lett. 439(3): 293-297.

31. Gilmore, I. R., Fox, S. P., Hollins, A. J., Sohail, M. & Akhtar, S. (2004) The design exogenous
delivery of siRNA for post-transcriptional gene silencing. J. Drug Target. 3: 147-155.

32. Judge, A. D. et al. (2005) Sequence-dependent stimulation of the mammalian innate inmune
response by synthetic siRNA. Nat. Biotechnol. 23(4): 457-462.

33. Kim, D. H. et al. (2004) Interferon induction by siRNAs and ssRNAs synthesized by fago
polymerase. Nat. Biotechnol. 22(3): 321-325.

34. Hornung, V. et al. (2005) Sequence-specific potent induction of IFN alpha by short interfering
RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11(3): 263-270.

35. Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D. W. (2006) RNAi therapeutics: a
potential new class of pharnmaceutical drugs. Nat. Chem. Biol. 2: 711-719.

36. Jackson, A. L. et al. (2006) Position-specific chemical modification of siRNAs reduce off-target
transcript silencing. RNA. 12: 1197-1205.

37. Reynlds, A. et al. (2004) Rational siRNA design for RNA interference. Nat. Biotechnol. 22: 326-
330.

38. Akhtar, S. & Benter, I. F. (2007) Nonviral delivery of synthetic siRNA in vivo. J. Clin. Invst.
117(12): 3623-3631.

39. Lin, X. et al. (2005) siRNA-mediated off-target gene silencing triggered by a 7 nt
complementation. Nucleic Acids Res. 33: 4527-4535.

40. Amarzguioui, M., Holen, T., Babaie, E. & Prydz, H. (2003) Tolerance for mutations and
chemical modifications in a siRNA. Nucleic Acids Res. 31: 589-595.

41. Morrissey, D. V. et al. (2005) Activity of stabilized short interfering RNA in a mouse model of
hepatitis B virus replication. Hepatology. 41: 1349-1356.

42. Li, W. & Szoka, F. C. Jr. (2007) Lipid-based nanoparticles for nucleic acid delivery. Pharm.
Res. 24: 438-449.

43. Soutschek, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic
administration of modified siRNAs. Nature. 432: 173-178.

44. Birmingham, A. et al. (2005) 3´UTR seeds matches, but not overall identity, are associated with
RNAi off-targets. Nat. Methods. 3: 199-204.

45. Ishihara, T., Goto, M., Kodera, K., Kanazawa, H., Murakami, Y., Mizushima, Y. & Higaki, M.
(2009) Intracellular delivery of siRNA by cell-penetrating peptides modified with cationic
oligopeptides. Drug Deliv. 16(3): 153-159.

46. Soutschek, K. et al. (2004) Therapeutics silencing of an endogenous gene by systemic
administration of modified siRNA. Nature. 432: 173-178.

47. Kim, S. H., Jeong, H. J., Lee, S. H., Kin, S. W. & Park, T. G. (2008) Local and sytemic delivery
of VEGF siRNA using polyelectrolite complex micelles for effective treatment of cancer. J.
Control. Rel. 129: 107-116.

48. Chu, T. C., Twu, K. Y., Ellington, A. D. & Levy, M. (2006) Aptamer mediated siRNA delivery.
Nucleic Acids Res. 34: e73.

49. Dassie, J. P., Liu, X. Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R.,
Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O. 2nd & Giangrande, P. H. (2009)
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-
expressing tumors. Nat. Biotechnol. 27(9): 839-849.

50. Schaffert, D. et al. (2008) Gene therapy progress and prospects: Synthetic polymer-based
systems. Gene Ther. 15: 1131-1138.

51. Fougerolles, A. R. (2008) Delivery vehicles for small interfering RNA in vivo. Human Gene
Ther. 19: 125-132.

52. Grayson, A. C., Doody, A. M. & Putnam, D. (2006) Biophysical and structural characterization
of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res. 23: 1868-2876.

53. Merkel, O. M., Librizzi, D., Pfestroff, A., Schurrat, T., Buyens, K., Sanders, N. N., De Smedt, S.
C., Béhé, M. & Kissel, T. (2009) Stability of siRNA polyplexes from poly(ethylenimine) and
poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on
pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and

47